DELCATH SYSTEMS, INC.
QUEENSBURY, NY · CIK 0000872912 · Medtech · Public
Hepatic chemotherapy delivery system for treating metastatic ocular melanoma
delcath.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $72M
- 7 Form D · Mar 2024
- 31 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 23
- 13 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,600,000 | |
| Private capital raised | Form D · SEC | $20,000,000 | |
| Private capital raised | Form D · SEC | $9,510,434 | |
| Private capital raised | Form D · SEC | $4,999,999 | |
| Private capital raised | Form D · SEC | $3,807,499 | |
| Private capital raised | Form D · SEC | $24,999,999 | |
| Private capital raised | Form D · SEC | $7,001,113 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1737 | BEAM - CA, LLC | — | — |
| 1738 | LUVOZO PBC | — | — |
| 1739 | Diopter Technologies | — | — |
| 1740 | DELCATH SYSTEMS, INC. | — | $72M |
| 1741 | SCISIO GENETICS, INC. | — | — |
| 1742 | MIVI Neuroscience, Inc. | — | $67M |
| 1743 | THEIA IMAGING LLC | — | $160K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Gilad AharonDirector
- Elizabeth CzerepakDirector
- Anthony DiasExecutive Officer
- David HoffmanExecutive Officer
- Johnny JohnExecutive Officer
- Barbra KeckExecutive Officer
- Gerard MichelDirector · Executive Officer
- Kevin MuirExecutive Officer
- Sandra PennellExecutive Officer
- John PurpuraExecutive Officer
- Martha RookExecutive Officer
- William RueckertDirector
- Steven SalamonDirector
- Jennifer SimpsonDirector · Executive Officer
- Roger StollDirector
- John SylvesterDirector
- Marco TagliettiDirector
- Vojo VukovicExecutive Officer
Patents
- Apparatus For Removing Chemotherapy Compounds From Bloodapplication
- Apparatus For Removing Chemotherapy Compounds From Bloodgranted
- Method of Selecting Chemotherapeutic Agents for an Isolated Organ or Regional Therapyapplication
- Filter and Frame Apparatus and Method of Useapplication
- Method of Selecting Chemotherapeutic Agents for an Isolated Organ or Regional Therapygranted
- Filter and Frame Apparatus and Method of Usegranted
- Apparatus For Removing Chemotherapy Compounds From Bloodgranted
- Apparatus For Removing Chemotherapy Compounds From Bloodgranted
- Filter and Frame Apparatus and Method of Usegranted
- Apparatus For Removing Chemotherapy Compounds From Bloodgranted
- Apparatus For Removing Chemotherapy Compounds From Bloodgranted
- Filter and Frame Apparatus and Method of Usegranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.